HOME >> MEDICINE >> NEWS
NIAID scientists unveil mechanism behind resistance to severe malaria

Scientists have discovered why people with a specific type of hemoglobin--the oxygen-carrying molecule that gives red blood cells their color--are less prone to severe malaria. In a series of experiments, the researchers determined how hemoglobin type C impairs the ability of malaria parasites to cause disease symptoms.

"This research gives us a new insight into malaria, a major global killer that preys especially on young children and claims a life every 30 seconds," notes Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, where the research was conducted.

"If we better understand the natural protective mechanisms against malaria, we might be able to mimic that protective effect through vaccines or drugs," says NIAID researcher Thomas E. Wellems, M.D., Ph.D., whose team's findings appear this week in the journal Nature.

Hemoglobin exists in several varieties. Hemoglobin A is the most common, but in parts of West Africa, where malaria is rife, one-fourth of the population has at least one gene for hemoglobin C. Children with at least one hemoglobin C gene are less prone to deadly cerebral malaria, in which parasite-infected red blood cells accumulate in the brain. But how hemoglobin C confers this protection has puzzled scientists until now.

To solve the mystery, Dr. Wellems and his colleagues studied laboratory-infected red blood cells and blood drawn from children with malaria from the African nation of Mali. Genetically, the samples fell into three groups: those with two genes for hemoglobin A (AA); those with two genes for hemoglobin C (CC); or those with one gene for each type of hemoglobin (AC).

The scientists then measured three phenomena that affect how well parasitized red blood cells can be made to stick to one another, to uninfected red blood cells and to blood vessel walls. These phenomena--known respectively as aggl
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
22-Jun-2005


Page: 1 2

Related medicine news :

1. NIAID releases MDR/XDR Tuberculosis research agenda
2. NIAID DNA vaccine for H5N1 avian influenza enters human trial
3. NIAID media availability: Examining genetic variability of malaria parasite offers insight
4. NIAID awards $4 million to develop anti-radiation treatments
5. Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
6. NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
7. NIAID study finds higher dose of flu vaccine improves immune response in the elderly
8. NIAID media availability: New study describes key protein from highly pathogenic H5N1 avian flu virus and how it might mutate
9. NIAID media availability: Understanding influenza infection
10. NIAID researchers show how promising TB drug works
11. NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... organization behind the New England Journal of Medicine and NEJM Journal Watch, announces ... Pediatrics Board Review was created by a panel of pediatricians from leading medical ...
(Date:3/27/2017)... Orion, Michigan (PRWEB) , ... March 27, 2017 ... ... results. The comprehensive weight management program at Women’s Excellence will help patients ... initial evaluation and physical exam. The specialists at Women's Excellence will measure ...
(Date:3/27/2017)... ... ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from California ... she said. , She thinks the coming week is going to be a very joyful ... to help my students.” , The award will allow the 4th grade teacher at Tumwater ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017  Twist ... high-quality DNA synthesis, today announced that it raised an ... a total of $166 million. "It ... as we expand our reach and continue to deliver ... in multiple market segments," commented Emily M. Leproust, Ph.D., ...
(Date:3/27/2017)...   Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company ... the Company,s Chief Operating Officer, is scheduled to present a corporate ... 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 ... ... 24th Annual Future Leaders in Biotech Industry – Friday, April 7, ...
(Date:3/24/2017)... PORTLAND, Oregon and PUNE, India , March 24, 2017 ... in 2015, and is estimated to reach $2,614 million by 2022, Globally, registering a ... expected to generate the highest revenue, and is projected to dominate the market during ... ... Allied Market Research Logo ...
Breaking Medicine Technology:
Cached News: